Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have earned an average recommendation of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $11.00.

A number of analysts have recently commented on the company. Lake Street Capital dropped their price target on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, March 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evaxion A/S in a research note on Thursday, June 11th. JonesTrading started coverage on Evaxion A/S in a report on Tuesday, March 10th. They issued a “buy” rating and a $10.00 target price on the stock. Wall Street Zen cut Evaxion A/S from a “buy” rating to a “hold” rating in a research note on Sunday, March 22nd. Finally, Maxim Group started coverage on Evaxion A/S in a report on Thursday, February 19th. They set a “buy” rating and a $10.00 price target for the company.

Evaxion A/S Stock Performance

Shares of EVAX stock opened at $3.05 on Friday. The company’s fifty day moving average price is $4.01 and its 200-day moving average price is $4.16. The stock has a market cap of $25.44 million, a PE ratio of -2.07 and a beta of 0.24. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41. Evaxion A/S has a 12 month low of $2.19 and a 12 month high of $12.15.

Evaxion A/S (NASDAQ:EVAX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.43). On average, equities analysts expect that Evaxion A/S will post -0.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of EVAX. Rathbones Group PLC bought a new position in shares of Evaxion A/S in the first quarter worth approximately $170,000. Renaissance Technologies LLC purchased a new position in Evaxion A/S in the 1st quarter worth approximately $146,000. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Evaxion A/S in the 1st quarter worth approximately $112,000. SmartHarvest Portfolios LLC bought a new position in Evaxion A/S in the 4th quarter valued at approximately $72,000. Finally, Wesbanco Bank Inc. bought a new position in Evaxion A/S in the 4th quarter valued at approximately $48,000. 11.04% of the stock is owned by hedge funds and other institutional investors.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.